What is LENZ (LENZ) stock price today?

LENZ (LENZ) is currently trading at $5.05, up 1.1% today.

What is LENZ P/E ratio?

LENZ's P/E ratio is -3.18. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is LENZ return on equity (ROE)?

LENZ's return on equity (ROE) is -28.87%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is LENZ's market cap?

LENZ has a market capitalization of $158.34M.

NMS · Biotechnology

LENZ (LENZ) Stock

$5.05 +1.10% NMS: LENZ Healthcare

Valuation

Metric	Value
Price	$5.05
Market Cap	$158.34M
P/E Ratio	-3.18
P/B Ratio	1.00
P/S Ratio	10.96
EPS (TTM)	$-2.85
52-Week High	$50.40
52-Week Low	$4.83
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-28.87%
ROA	-26.80%
ROCE	-32.04%
Gross Margin	-478.95%
Operating Margin	-478.95%
Net Margin	-5.19%
Debt/Equity	0.00
Current Ratio	13.90

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$15.0M	$0	$0	$19.0M
Operating Profit	$-60.0M	$-10.0M	$-72.0M	$-59.0M	$-91.0M
Net Profit	$-71.0M	$-11.0M	$-70.0M	$-50.0M	$-82.0M
EPS	$-8.54	$-12.89	$-15.30	$-2.34	$-2.85
Op Margin	—	-69.9%	—	—	-477.5%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$18.0M	$47.0M	$70.0M	$215.0M	$306.0M
Total Liabilities	$33.0M	$71.0M	$163.0M	$11.0M	$22.0M
Cash	$18.0M	$44.0M	$35.0M	$20.0M	$25.0M
Borrowings	$0	$0	$0	$1.0M	$0

Latest News

LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions Simply Wall St. · Jul 11, 2026 LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia GlobeNewswire · Jul 6, 2026 LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand GlobeNewswire · Jun 24, 2026 LENZ Therapeutics adds China partner for presbyopia drug VIZZ Proactive · Jun 8, 2026 LENZ Therapeutics to Receive VIZZ Payments From Everest-Corxel Deal MT Newswires · Jun 8, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-53.0M	$-88.0M	$-60.0M	$-59.0M	$-69.0M
Investing Cash Flow	$-11.0M	$-248.0M	$-30.0M	$-155.0M	$-76.0M
Financing Cash Flow	$0	$0	$-2.0M	$119.0M	$0
Net Cash Flow	$357.0M	$-329.0M	$-9.0M	$-15.0M	$5.0M
Free Cash Flow	$-59.0M	$-95.0M	$-60.0M	$-60.0M	$-70.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-37.99%
Quick Ratio	10.26
Interest Coverage	—
Return 1Y	-85.38%
Return 3Y	-43.74%
Return 5Y	-94.03%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ABUS	$4.41	+0.00%	-25.41	$871.14M	0.00%
GERN	$1.34	-4.29%	23.17	$859.64M	0.00%
GHRS	$29.10	-0.06%	-10.34	$2.00B	0.00%
MRVI	$6.90	+3.06%	-4.48	$1.90B	0.00%
NBTXNanobiotix S.A.	$40.18	+1.21%	-68.71	$2.03B	0.00%

About LENZ

LENZ is led by CEO Evert Schimmelpennink, employs 6 people, headquartered in US, publicly traded since 2024.

LENZ stock trades at $5.05 with a market capitalization of $158.34M. The stock is valued at a price-to-earnings (P/E) ratio of -3.18, price-to-book of 1.00, price-to-sales of 10.96. Over the past 52 weeks the stock has ranged between $4.83 and $50.40, and currently trades 90.0% below its 52-week high.

On profitability, LENZ generates a return on equity (ROE) of -28.87%, return on capital employed of -32.04%, an operating margin of -478.95%, a net profit margin of -5.19%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides